Madrigal Pharmaceuticals Inc MDGL:NASDAQ

Last Price$76.98NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/24/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$73.74 (4)
Ask (Size)$79.00 (1)
Day Low / HighN/A - N/A
Volume268.4 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 01/24/2020

 

Madrigal Pharmaceuticals Inc ( NASDAQ )

Price: $76.98
Change: -4.70 (5.75%)
Volume: 268.4 K
4:00PM ET 1/24/2020
 
 

Supernus Pharmaceuticals Inc ( NASDAQ )

Price: $23.57
Change: -0.64 (2.64%)
Volume: 403.3 K
4:00PM ET 1/24/2020
 
 

Revance Therapeutics Inc ( NASDAQ )

Price: $21.78
Change: -0.54 (2.42%)
Volume: 656.2 K
4:00PM ET 1/24/2020
 
 

Portola Pharmaceuticals Inc ( NASDAQ )

Price: $13.65
Change: -0.10 (0.73%)
Volume: 1.7 M
4:00PM ET 1/24/2020
 
 

Aerie Pharmaceuticals Inc ( NASDAQ )

Price: $21.50
Change: -1.06 (4.70%)
Volume: 1.6 M
4:00PM ET 1/24/2020
 

Read more news Recent News

Analyst Actions: UBS Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Lifts Price Target to $127 From $125
10:56AM ET 1/09/2020 MT Newswires

Madrigal Pharmaceuticals' (MDGL) average rating among analysts is a buy, with an average price target of $156. Price: 90.66, Change: +4.01, Percent Change:...

Madrigal Pharmaceuticals Initiates Second Phase 3 Trial of Resmetirom in Non-Alcoholic Fatty Liver Disease
7:32AM ET 12/18/2019 MT Newswires

Madrigal Pharmaceuticals (MDGL) said pre-market Wednesday that it has commenced dosing in the second Phase 3 clinical trial of resmetirom in patients with...

Insider Sales at Madrigal Pharmaceuticals (MDGL) are Significant
10:18PM ET 12/16/2019 MT Newswires

There was a notable level of share sales at Madrigal Pharmaceuticals by insiders today, as revealed in form 4 documents filed with the SEC. Two insiders...

Insider Trends: Insider 90-Day Selling Trend Extended at Madrigal Pharmaceuticals
2:21PM ET 12/13/2019 MT Newswires

Bay City Capital Llc, 10% Owner, sold 1,200,000 shares of Madrigal Pharmaceuticals (MDGL) on Dec 13, 2019, for $126,564,000. Subsequent to the Form 4...

View all Commentary and Analysis

FDA Decision For Intercept's NASH Drug Ocaliva Delayed; Opportunity Presents Itself
1:57PM ET 1/20/2020 Seeking Alpha

Madrigal: Beyond NASH
12:35PM ET 1/14/2020 Seeking Alpha

NGM NASH Data Was Preliminary, But More Important Biopsy Data On Its Way Early 2020
11:15AM ET 10/22/2019 Seeking Alpha

Madrigal: A Basic Overview
12:48PM ET 9/26/2019 Seeking Alpha

Company Profile

Business DescriptionMadrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA. View company web site for more details
Address200 Barr Harbor Drive
West Conshohocken, Pennsylvania 19428
Phone+1.484.380.9263
Number of Employees17
Recent SEC Filing12/13/20194/A
Chairman, President & Chief Executive OfficerPaul A. Friedman
CFO, Principal Accounting Officer & Senior VPMarc R. Schneebaum
Director & Chief Medical OfficerRebecca A. Taub
Senior Vice President & General CounselBrian J. Lynch

Company Highlights

Price Open$82.02
Previous Close$81.68
52 Week Range$76.90 - 148.18
Market Capitalization$1.2 B
Shares Outstanding15.4 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement02/26/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.40
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-14.69%

Analyst Ratings as of 01/08/2020

Buy
10
Overweight
0
Hold
2
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset